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Status Epilepticus (SE) is associated with significant mortality and accounts for ~10% of 
epilepsy-related deaths. Epilepsy and SE mortality data from 2001 to 2013, in addition to 
annual age group populations for England and Wales, were obtained from the Office of 
National Statistics website (www.ons.gov.uk). Age-adjusted mortality rates for epilepsy and 
SE with 95% Confidence Intervals (CI) were calculated using the European Standard 
Population. Trends in mortality rates of both Epilepsy and SE were investigated using the 
Spearman coefficient. The crude mean Epilepsy mortality rate per 100,000 person years 
between 2001 and 2013 was 1.87 (95% CI 1.83, 1.91) with a corresponding SE mortality 
rate of 0.14 (95% CI 0.13, 0.15). The mean age-adjusted Epilepsy mortality rate per 100000 
person years was 3.24 (95% CI 3.12, 3.35) with a corresponding SE mortality rate of 0.24 
(95% CI 0.21, 0.27). All Epilepsy deaths significantly decreased from 2001 to 2013 
(Spearman’s Rho -0.733, p=0.004); this decrease was predominantly due to a decrease in 
SE deaths (Spearman’s Rho -0.917, p<0.001). In summary our finding supports the 
hypothesis that the policy of early and aggressive treatment of SE may be improving the 
prognosis of this condition in England and Wales. 
 
 
 
 
 
 
 
 
 
 
 
 
Status epilepticus (SE) has a high mortality rate (10-20%), accounting for ~10% of epilepsy-
related deaths1. SE has traditionally been defined as a seizure lasting 30 minutes or more, 
but treatment at this stage may be too late to prevent serious consequences (this has 
resulted in a proposal to change the definition of SE)2.  
A major advance in the last two decades has been the proposal, first advocated by 
Lowenstein and colleagues in 1999, that prolonged convulsive seizures (>5 minutes) be 
considered as “operational” SE with prompt , more aggressive treatment3. The need for two 
dimensions is recognised in the recent ILAE definition and classification of SE, which defines 
two time points: t1, - the operational definition of SE (the time point at which a seizure should 
be regarded as an “abnormally prolonged seizure”) and t2 – the traditional definition of SE 
(the time of on-going seizure activity beyond which there is a risk of long-term 
consequences)4.  
We wished to determine if this drive to earlier, more aggressive treatment has been 
associated with a change in SE mortality in England and Wales. 
 
Methods 
Epilepsy mortality data and annual age group populations for England and Wales were 
obtained from the Office of National Statistics website (www.ons.gov.uk). Prior to 2001, 
mortality rates were classified using the WHO ICD-9 classification, with the WHO ICD-10 
classification employed thereafter. Consequently direct comparison of mortality rates pre- 
and post-2001 was not felt to be feasible. The majority of epilepsy deaths were classified as 
“epilepsy (not otherwise specified)”, which may include some deaths due to SE, 
consequently underestimating SE mortality. There is however no reason to believe that this 
rate of misclassification would differ from year to year5. 
Age-adjusted mortality rates for epilepsy and SE with 95% Confidence Intervals (CI) were 
calculated using the European Standard Population (first introduced in 1976), using the 
Office of National Statistics guidelines6.(see eTable1).We used the Spearman coefficient to 
measure trends in mortality rates of both epilepsy and SE. Statistics were calculated using 
SPSS v22. A p-value <0.05 was considered statistically significant.   
 
Results  
 The number of annual deaths attributable to epilepsy was relatively stable with a mean 
annual total of 1021 deaths (95% CI 1000, 1042), with a corresponding annual mean of 77 
deaths (95% C.I. 70, 83) attributable to SE, accounting for 7.5% (95% CI 6.8, 8.2) of the 
deaths attributable to epilepsy over the 13 years. The crude mean epilepsy mortality rate per 
100,000 person years between 2001 and 2013 was 1.87 (95% CI 1.83, 1.91) with an SE rate 
of 0.14 (95% CI 0.13, 0.15) (Table 1). The mean age-adjusted epilepsy mortality rate per 
100,000 person years was 3.24 (95% CI 3.12, 3.35) with a corresponding SE mortality rate 
of 0.24 (95% CI 0.21, 0.27).  There was a significant trend towards reduced mortality for all 
age-adjusted epilepsy deaths between 2001 and 2013 (Spearman’s Rho -0.733, p=0.004) 
that was mainly accounted for by a reduction in age-adjusted SE deaths (Spearman’s Rho -
0.917, p<0.001) rather than non-SE epilepsy deaths (Spearman’s Rho -0.544, p=0.055). 
Indeed, the temporal trends for SE and non-SE deaths diverge over that period (Figure 1). 
 
Discussion 
We examined epilepsy- and SE-related mortality rates in England & Wales between 2001 & 
2013. Whereas  the overall total annual deaths attributable to epilepsy remained relatively 
stable, despite a population increase of 4,588,251, the annual number of SE-related deaths 
is falling (as evidenced by the significant trend for unadjusted SE mortality rates). More 
encouragingly, the age adjusted mortality rates for both SE and all epilepsy deaths are 
decreasing. Whilst it would be informative to know at what time point an operational 
diagnosis of SE was adopted, the data do not allow for such precision. The expectation is 
however that any change would have been gradual, as is mirrored by the gradual 
incorporation of an operational diagnosis of SE into the proposed treatment protocols of SE 
of professional bodies such as those of the EFNS (2010)7 and the Neurocritical Care Society 
(2012)8. 
There is a paucity of data regarding temporal trends in SE mortality, with this being the first 
such report from the United Kingdom; the only previous significant SE study from the UK 
was the North London Convulsive Status Epilepticus in Childhood Surveillance Study 
(NLCSECSS)9. Previous mortality SE estimates have come from seven population based SE 
studies (and single institution cohort studies)1, only one of which was carried out over 
several years (so allowing for an examination of SE mortality trends). In this study the 
incidence and case fatality (CF) for generalised convulsive SE in the state of California 
(1991-1998) were calculated using a state-wide database of all people with a hospital 
diagnosis of SE10. The overall case fatality was 10.7%, but with a much lower rate of 3.5% 
for those admitted with a primary diagnosis of generalised convulsive SE. Whilst the overall 
mortality for SE remained stable over the period of observation, the mortality of those 
admitted with a primary diagnosis of SE decreased from 4.7% to 3.2%. At the same time the 
annual incidence of SE decreased by 42% between 1991 and 1998 from 8.5 to 4.9/100,000 
(p<0.001), possibly suggesting more efficient and aggressive treatment of out-of-hospital 
prolonged seizures and SE.10 
Two more recent studies have looked at trends in SE-related hospital admissions and 
mortality in the United States, using representative samples of hospitals from national 
databases.11 12 In one study, data from the US National Hospital Discharge Survey were 
used to identify hospital discharges with SE between 1979 and 2010.11 In total 760,117 
discharges with SE were identified over the 32 years. In that time the incidence of SE 
increased from 3.5/100,000/year in 1979 to 12.5/100,000/year in 2010, representing an 
overall increase of 12.5% per year, with the most significant increase occurring between 
1979 and 1991 (17.7% annual increase). There was a subsequent decrease in the incidence 
of SE in the 1990s before a further increase in the 2000s. The corresponding cumulative in-
hospital mortality was 9.2% (95% CI 9.1,9.2) with no significant observed variation over the 
32 years. 
The second study utilised the Healthcare Cost and Utilisation Project Nationwide Inpatient 
Sample data to identify SE hospital admissions and SE-associated mortality between 1999 
and 2010.12 When considered as the primary cause of death, the age-adjusted mortality rate 
for SE increased by 5.6% between 1999 and 2010 from 0.179/100,000 to 0.189/100,000, 
with a corresponding increase of 56.4% in age-standardised SE hospital admissions from 
8.86/100000 in 1999 to 13.86/100,000 in 2010.9 All three US studies used the WHO ICD-9 
coding system.  
In comparing the three US studies and our findings several observations can be made. 
Whilst the earlier California study10 was confined to admissions with generalised convulsive 
SE, the later studies11,12 included all cases of SE. Greater recognition of subtle cases of SE 
and non-convulsive SE, particularly in the ICU setting with the greater availability of 
ambulatory EEG, is likely to be a significant factor in the reported increase in the incidence 
of SE over the past two decades.13 14 The nature of the databases in those studies did not 
allow for a sub-analysis of trends in the incidence and mortality of generalised convulsive 
and non-convulsive SE respectively. Overall the reported age-standardised mortality rate for 
SE of approximately 0.2/100,00012 is comparable to that seen in our study yet reasons for 
the failure to see a similar decrease in SE mortality over the last decade are not immediately 
evident. Whilst differences in SE mortality rates (which were broadly similar) may be partially 
explained by different coding systems, it is unlikely to be the explanation for the difference in 
mortality rates as the rate of misclassification of the primary cause of death would not be 
expected to differ significantly from year to year.5 More plausible explanations may be 
variation in population demographics, with a higher incidence (and mortality) of SE in non-
white populations15, differences in healthcare access in the US12 and differences in 
attribution of cause of death (e.g. status epilepticus in coma may be more likely to be 
classed as a cause of death in one country rather than another).16  This underlines the need 
for a uniformly accepted definition and classification of SE such as that recently proposed by 
the ILAE Task Force4, and perhaps more pertinently in the context of mortality, one for non-
convulsive SE. 
One of the major limitations of this study is that it provides a snapshot on national mortality 
data for Epilepsy and SE without the corresponding incidence rates. Consequently we are 
unable to comment on whether there has been an increase in the incidence of SE since 
2001 (in line with the US Studies), or whether the observed decrease in SE mortality is 
mirrored (and therefore partially explained) by a corresponding decrease in the incidence of 
SE. This merits further study. Indeed the primary alternative hypothesis for the observed fall 
in SE mortality is that this is due to a corresponding fall in the incidence of SE due to 
possibly improved treatments. This is nevertheless counterintuitive, as it would not be 
expected that there would be such a difference between the UK and the US. The change in 
temporal definition (to an earlier time point) would, if anything, lead to a greater number of 
epilepsy-related deaths being classified as SE-related, which would, in turn, increase (not 
reduce) the number of SE deaths (and therefore cannot explain our results). A further 
limitation of the current study is that it only examines mortality trends since 2001. This, 
however, is in line with our hypothesis that the advocacy for more aggressive and earlier 
treatment of prolonged seizures, as mandated by Lowenstein and colleagues,3 was the 
catalyst for improved SE management and prognosis. Changes in the national coding 
system (from WHO ICD-9 to ICD-10) also determined our cut-off point.    
In summary our finding supports the hypothesis that the policy of early and aggressive 
treatment of SE may be improving the prognosis of this condition in England and Wales. Our 
figures are similar to those obtained for SE associated deaths in the US11,12, where a similar 
trend for fewer SE deaths was however not found. There may be a number of explanations 
for this difference including differences in the structures of and access to health care 
systems and methodological considerations in the attribution of cause of death.  
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Table 1: Epilepsy and Status Epilepticus Mortality (Crude and Age-Adjusted) rates in 
England & Wales 2001-13. 
Year Population 
Total 
epilepsy 
deaths 
Crude 
epilepsy 
mortality 
(per 
100,000) 
Age-adjusted 
epilepsy 
mortality (per 
100,000) (95% 
CI) 
SE 
deaths 
(total 
%) 
Crude SE 
mortality 
(per 
100,000) 
Age-adjusted 
SE mortality  
(per 100,000) 
(95% CI) 
2001 52,359,978 1,014 1.94 3.53 (3.31–3.74) 87 (8.6) 0.17 0.32 (0.25–0.39) 
2002 52,602,143 953 1.81 3.07 (2.87–3.26) 91 (9.5) 0.17 0.32 (0.25–0.38) 
2003 52,863,238 1,075 2.03 3.56 (3.35–3.78) 85 (7.9) 0.16 0.28 (0.22–0.34) 
2004 53,152,022 980 1.84 3.28 (3.07–3.48) 85 (8.7) 0.16 0.29 (0.23–0.35) 
2005 53,575,343 1,059 1.98 3.5 (3.29–3.71) 77 (7.3) 0.14 0.25 (0.19–0.31) 
2006 53,950,854 1,018 1.89 3.32 (3.12–3.53) 84 (8.3) 0.16 0.28 (0.22–0.34) 
2007 54,387,392 998 1.83 3.19 (2.99–3.39) 69 (6.9) 0.13 0.22 (0.17–0.27) 
2008 54,841,720 1,045 1.91 3.33 (3.13–3.53) 66 (6.3) 0.12 0.21 (0.16–0.26) 
2009 55,235,253 1,016 1.84 3.16 (2.97–3.35) 79 (7.8) 0.14 0.25 (0.19–0.30) 
2010 55,692,423 1,006 1.81 3.07 (2.88–3.26) 55 (5.5) 0.10 0.17 (0.13–0.22) 
2011 56,170,927 1,006 1.79 3.07 (2.88–3.26) 69 (6.9) 0.12 0.19 (0.15–0.24) 
2012 56,567,796 1,066 1.88 3.02 (2.83–3.20) 80 (7.5) 0.14 0.20 (0.15–0.24) 
2013 56,948,229 1,040 1.83 3.02 (2.84–3.20) 68 (6.5) 0.12 0.18 (0.14–023) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Trends in age-adjusted non-SE Epilepsy (red) and SE (black) mortality rates with 
95% Confidence Intervals (dotted lines) in England & Wales 2001-2013. 
 
